SIA
JSPRW

SkyView Investment Advisors’s Japer Therapeutics Warrants JSPRW Stock Holding History

SkyView Investment Advisors’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+302
New +$5 ﹤0.01% 333
2023
Q2 		– Sell
-302
Closed – – 803
2023
Q1 		$0 Hold
302
– – ﹤0.01% 724
2022
Q4 		$0 Hold
302
– – ﹤0.01% 497
2022
Q3 		$0 Hold
302
– – ﹤0.01% 555
2022
Q2 		$0 Hold
302
– – ﹤0.01% 606
2022
Q1 		$0 Buy
302
+300
+15,000% +$167 ﹤0.01% 610
2021
Q4 		$0 Buy
+2
New +$3 ﹤0.01% 577

Other funds holding JSPRW

BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SkyView Investment Advisors's JSPRW Position: Q2 2026 in Review

SkyView Investment Advisors opened a new position in Japer Therapeutics Warrants (JSPRW) in Q2 2026: 302 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #333 among its holdings. This is a return to the name: SkyView Investment Advisors previously reported a position in JSPRW as recently as Q1 2023.

SkyView Investment Advisors first reported a position in JSPRW in Q4 2021 and has held it in 7 quarters since. 7 funds tracked by Wall St. Rank hold JSPRW as of Q2 2026.

  • SkyView Investment Advisors held 302 shares of Japer Therapeutics Warrants worth $0 as of Q2 2026.
  • Japer Therapeutics Warrants was a new SkyView Investment Advisors position in Q2 2026.
  • Japer Therapeutics Warrants made up ﹤0.01% of SkyView Investment Advisors's portfolio in Q2 2026, its #333 holding.
  • SkyView Investment Advisors first reported a position in Japer Therapeutics Warrants in Q4 2021 and has held it in 7 quarters since.
  • 7 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2026.

Based on SkyView Investment Advisors's 13F filing for Q2 2026, filed 15 Sep 2026.